We are live on ! Find out more
ALLR

Allarity Therapeutics
ALLR

3 hedge funds and large institutions have $31.8K invested in Allarity Therapeutics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

14.16% less ownership

Funds ownership: 15.15% → 0.99% (-14%)

50% less funds holding

Funds holding: 6 → 3 (-3)

94% less capital invested

Capital invested by funds: $516K → $31.8K (-$484K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$14.6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$268K
2
AC
Armistice Capital
New York
-$195K
3
Citadel Advisors
Citadel Advisors
Florida
-$19.6K
4
VF
Virtu Financial
New York
-$6.24K

ALLR Hedge Fund Activity: Q4 2023 in Review

3 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q4 2023, worth a combined $31.8K — down 94% from $516K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ALLR and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Securities, adding an estimated $14.6K. The largest seller was Sabby Management, exiting entirely with an estimated $268K sold.

  • 3 institutional investors held Allarity Therapeutics (ALLR) as of Q4 2023, down from 6 in Q3 2023.
  • Funds reported $31.8K of Allarity Therapeutics stock for Q4 2023, down 94% quarter-over-quarter.
  • 0 funds opened new Allarity Therapeutics positions in Q4 2023 and 3 closed out, a net change of -3 holders.
  • The largest Allarity Therapeutics buyer in Q4 2023 was Two Sigma Securities, an estimated $14.6K added.
  • The largest Allarity Therapeutics seller in Q4 2023 was Sabby Management, an estimated $268K sold.

Based on aggregated 13F filings for Q4 2023.